Annual report pursuant to Section 13 and 15(d)

SEGMENT REPORTING

v3.23.1
SEGMENT REPORTING
 12 Months Ended
Dec. 31, 2022
Segment Reporting [Abstract]  
SEGMENT REPORTING SEGMENT REPORTING
Operating segments include components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker (the Company’s Chief Executive Officer, “CEO”) in deciding how to allocate resources and in assessing the Company’s performance.
Operating segments for the Company are organized by product type and managed by segment managers who are responsible for the operating and financial results of each segment. Due to the similarities in the manufacturing and distribution processes for the Company’s products, much of the information provided in these consolidated financial statements and the footnotes to the consolidated financial statements, is similar to, or the same as, that information reviewed on a regular basis by the Company’s CEO.

The Company’s management evaluates segment profit/loss for each of the Company’s operating segments. The Company defines segment profit/loss as income from continuing operations before interest, taxes, depreciation, amortization, share-based compensation expense, gains/losses on foreign currency fluctuations, gains/losses on the early extinguishment of debt and miscellaneous expenses. Segment profit/loss also excludes the impact of certain items that are not directly attributable to the reportable segments’ underlying operating performance. Such items are shown below in the table reconciling segment profit to consolidated income from continuing operations before income taxes. The Company does not have any material inter-segment sales. Information about total assets by segment is not disclosed because such information is not reported to or used by the Company’s CEO. Segment goodwill and other intangible assets, net, are disclosed in Note 9 Goodwill and Note 8 Intangible Assets, respectively.
As of December 31, 2022 and 2021, the Company’s operations were organized in the following two reportable segments:
1.The Cannabinoid operating segment: comprised of the Company’s cultivation, extraction, and commercialization of cannabinoid products. This operating segment is in the early stages of commercializing cannabinoid products internationally pursuant to applicable international and domestic legislation, regulations, and other permits. The Company’s principal customers and sales for its products are primarily outside of the U.S.
2.Non-Cannabinoid operating segment: comprised of the brands acquired as part of the Herbal Brands acquisition in May 2019. The segment is engaged in the business of formulating, manufacturing, marketing, selling, distributing, and otherwise commercializing nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements. The Company’s principal customers for its Herbal Brands products include mass retailers, specialty and health retailer and distributors in the U.S.
The following table is a comparative summary of the Company’s net sales and segment profit for by reportable segment for the periods presented:
Year ended
  December 31,
2022		 December 31,
2021
Segment Net Revenue:
Cannabinoid $ 6,119  $ 3,242 
Non-Cannabinoid 11,681  12,132 
Total Net Revenue 17,800  15,374 
 
Segment Profit (Loss):
Cannabinoid (63,720) (16,915)
Non-Cannabinoid 1,346  2,631 
Total Loss $ (62,374) $ (14,284)
 
Reconciliation:
Total Segment Loss (62,374) (14,284)
Unallocated corporate expenses (8,327) (11,196)
Non-cash share based compensation (2,343) (11,451)
Depreciation and amortization (2,058) (1,768)
Goodwill impairment —  (18,508)
Loss from operations $ (75,102) $ (57,207)
 
Loss (gain) on debt extinguishment, net 2,263  (3,262)
Gain on remeasurement of warrant liability (2,092) (16,856)
Gain on investment (6,851) — 
Foreign exchange loss 1,129  1,276 
Interest expense 2,702  6,818 
Other expense (income), net 202  (502)
Loss from operations before income taxes and equity investment loss $ (72,455) $ (44,681)

Customers with an accounts receivable balance of 10% or greater of total accounts receivable and customers with net revenue of 10% or greater of total revenues are presented below for the periods indicated:
Percentage of Revenues Percentage of Accounts Receivable
December 31, December 31,
2022 2021 2022 2021
Customer B (a)
12% 17% 18% 25%
Customer C (b)
* * 13% 18%
Customer H (a)
* * 15% *
Customer I (a)
* * 10% *
* denotes less than 10%

(a) net sales attributed are reflected in the cannabinoid segments
(b) net sales attributed are reflected in the non-cannabinoid segments

During 2022 and 2021, the Company's net sales for the non-cannabinoid segment were in the U.S; cannabinoid net sales were mostly outside of the U.S., primarily in Colombia, Israel, Brazil and Australia.

The following table disaggregates the Company’s long-lived assets, by segment for the periods presented:
December 31,
2022		 December 31,
2021
Long-lived assets
   
Cannabinoid $ 15,308  $ 30,709 
Non-Cannabinoid
155  216 
Other(a)
—  7 
Total $ 15,463  $ 30,932 
____________
(a)“Other” includes long-lived assets primarily in the Company’s corporate offices.
Long-lived assets consist of non-current assets other than goodwill; intangible assets, net; deferred tax assets; investments in unconsolidated subsidiaries and equity securities; and financial instruments. The Company’s largest market in terms of long-lived assets is in Colombia.
The following table disaggregates the Company’s revenues by channel for the periods presented:
  Year ended
  December 31,
2022		 December 31,
2021
Mass retail $ 9,920  $ 8,070 
Distributors 6,796  5,835 
Specialty, health and other retail 578  945 
E-commerce 506  524 
$ 17,800  $ 15,374 


The following table represents the Company's revenues attributed to countries based on location of customer:
Year Ended December 31,
2022 2021
United States $ 11,461  $ 12,132 
Israel 1,424  $ 809 
Australia 1,835  1,584 
Brazil 1,431  153 
Germany 1,431  100 
Other 218  596 
 Total $ 17,800  $ 15,374 
(a) The Company has presented December 31, 2021 information to conform to the current period presentation.